PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 25, 2026Journal of Medical Economics0 citationsOpen Access

Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis

View Full Paper
YDYanan DongZMZiling MaoADAnnaliza Dominguez

Key Points

  • The aim is to evaluate treatment switching and associated healthcare costs in Medicare patients with chronic migraine receiving onabotulinumtoxinA or CGRP monoclonal antibodies.
  • Retrospective claims analysis of Medicare patients
  • Comparison of treatment switch rates between onabotulinumtoxinA and CGRP mAb
  • Cost analysis for both treatment groups
  • Patients on CGRP mAb are more likely to switch migraine treatments within the first 12 months than those on onabotulinumtoxinA.
  • Total healthcare costs for both treatments appear comparable.

Abstract

Patients with CM on a CGRP mAb were significantly more likely to switch to a different branded migraine preventive treatment within 12 months of treatment initiation compared to those on onabotA. Total costs were comparable between treatments.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dong et al. (2026) studied this question.

synapsesocial.com/papers/699e919cf5123be5ed04f36fhttps://doi.org/10.1080/13696998.2026.2630604
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine2026
  2. 2Comparative effectiveness and tolerability of calcitonin gene‐related peptide (<scp>CGRP)</scp> monoclonal antibodies and <scp>onabotulinumtoxinA</scp> in chronic migraine: A multicenter, real‐world study in Taiwan2024 · 3 citations
  3. 3Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study2026
  4. 4Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program2026 · 1 citations
  5. 5Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland2024 · 3 citations